Home

Jonathan I Lieber

CIK 1350090 · Chief Financial Officer · last filed 2026-09-02

Jonathan I Lieber is a Chief Financial Officer who has filed 33 SEC Form 4 insider transactions across 6 companies since 2007. The most recent filing, for DCOY, was dated Sep 2, 2026. Across all open-market trades the lifetime net is −$242.0K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.6M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$2.57M

Companies

6

Total Filings

33

Lifetime Open-Market Net

-$242.0K

Filer Profile

Reported Address
C/O HISTOGENICS CORPORATION
830 WINTER STREET #3
WALTHAM, MA 02451
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
DCOY Director 2,002 $2.67 $5.3K $0 1 2026-09-02
RLYB Chief Financial Officer 4,904 $16.88 $82.8K $22.1K 5 2026-02-23
Salarius Pharmaceuticals, Inc. (SLRX) Delisted Director 24 $0.84 $20 $7.0K 6 2024-02-22
APPLIED GENETIC TECHNOLOGIES CORP (AGTC) Delisted Chief Financial Officer — $0.39 — $0 3 2022-12-01
RGEN CFO 15,000 $165.18 $2.48M $0 1 2013-03-12
Altus Pharmaceuticals Inc. (ALTU) Delisted SVP, CFO and Treasurer 0 $10.12 $0 -$271.1K 11 2008-05-27

Recent Filings

33 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-09-02 DCOY Grant (A) +2,000 $0 EDGAR
2026-02-23 RLYB Mixed +1,711 -$4.0K EDGAR
2025-02-19 RLYB Grant (A) — $0 EDGAR
2024-02-22 Salarius Pharmaceuticals, Inc. (SLRX) Delisted Grant (A) — $0 EDGAR
2024-02-16 RLYB Grant (A) — $0 EDGAR
2023-03-16 RLYB Buy (P) +5,000 $26.1K EDGAR
2023-02-01 RLYB Grant (A) — $0 EDGAR
2023-01-05 Salarius Pharmaceuticals, Inc. (SLRX) Delisted Grant (A) +1,440 $0 EDGAR
2022-12-01 APPLIED GENETIC TECHNOLOGIES CORP (AGTC) Delisted Disp (D) — $0 EDGAR
2022-08-24 APPLIED GENETIC TECHNOLOGIES CORP (AGTC) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 33
Page 1 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.